Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TREACE MEDICAL CONCEPTS, INC.

(TMCI)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
22.07 USD   -2.95%
09/30Insider Sell: Treace Medical Concepts
MT
09/28Treace Medical Concepts, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
09/27Treace Medical Concepts Appoints New Directors
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Treace Medical Concepts: Q2 Earnings Snapshot

08/09/2022 | 05:52pm EDT

PONTE VEDRA, Fla. (AP) _ Treace Medical Concepts Inc. (TMCI) on Tuesday reported a loss of $17.2 million in its second quarter.

The Ponte Vedra, Florida-based company said it had a loss of 31 cents per share. Losses, adjusted to extinguish debt, were 23 cents per share.

The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share.

The orthopedic medical device maker posted revenue of $30 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $28.7 million.

Treace Medical Concepts expects full-year revenue in the range of $130 million to $134 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TMCI at https://www.zacks.com/ap/TMCI

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about TREACE MEDICAL CONCEPTS, INC.
09/30Insider Sell: Treace Medical Concepts
MT
09/28Treace Medical Concepts, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
09/27Treace Medical Concepts Appoints New Directors
GL
09/27Treace Medical Concepts Appoints New Directors
AQ
09/27Treace Medical Concepts, Inc. Announces the Appointment of Lance E. Berry and Jane E. K..
CI
09/21BTIG Raises Price Target on Treace Medical Concepts to $28 From $23, Keeps Buy Rating
MT
09/21Stifel Nicolaus Adjusts Treace Medical Concepts Price Target to $27 From $24, Maintains..
MT
09/20Transcript : Treace Medical Concepts, Inc. - Special Call
CI
09/19Insider Sell: Treace Medical Concepts
MT
09/19Treace Medical Concepts, Inc.(NasdaqGS:TMCI) added ..
CI
More news
Analyst Recommendations on TREACE MEDICAL CONCEPTS, INC.
More recommendations
Financials (USD)
Sales 2022 132 M - -
Net income 2022 -50,8 M - -
Net cash 2022 24,4 M - -
P/E ratio 2022 -24,0x
Yield 2022 -
Capitalization 1 223 M 1 223 M -
EV / Sales 2022 9,05x
EV / Sales 2023 7,33x
Nbr of Employees 248
Free-Float 59,7%
Chart TREACE MEDICAL CONCEPTS, INC.
Duration : Period :
Treace Medical Concepts, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TREACE MEDICAL CONCEPTS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 22,07 $
Average target price 28,75 $
Spread / Average Target 30,3%
EPS Revisions
Managers and Directors
John T. Treace Chief Executive Officer & Director
Mark L. Hair Chief Financial Officer
James T. Treace Chairman
Shana R. Zink Senior VP-Clinical Affairs
Terry Lubben Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
TREACE MEDICAL CONCEPTS, INC.18.40%1 223
SHOCKWAVE MEDICAL, INC.55.93%9 990
NOVOCURE LIMITED1.20%7 958
MASIMO CORPORATION-51.79%7 415
PENUMBRA, INC.-34.01%7 184
GETINGE AB-51.48%4 702